The company has world-class expertise in medicinal chemistry and an experienced management team led by CEO Peter Worrall, CSO Professor Malcolm Stevens OBE, FRS and Research Director Dr Marc Hummersone. Between them the Pharminox team have proven track records in the discovery and development of several leading marketed anti-cancer agents, including the blockbuster drugs temozolomide (Temodar, Merck & Co, Inc) and erlotinib (Tarceva, Roche-Genentech and OSI Pharmaceuticals). Pharminox was formed in 2002 as a spin-out from Oxford University. Our operations are now based at the BioCity facility in Nottingham, UK.
View Top Employees from Pharminox LimitedWebsite | http://www.pharminox.com |
Revenue | $8 million |
Employees | 303 (303 on RocketReach) |
Founded | 2002 |
Phone | +44 115 912 4524 |
Industry | Pharmaceuticals, Biotechnology, Drug Discovery, Healthcare, Science and Engineering, Drug Manufacturing & Research, Pharmaceutical, Health Care |
SIC | SIC Code 2834 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Pharminox Limited employee's phone or email?
The Pharminox Limited annual revenue was $8 million in 2023.
Peter Worrall is the CEO of Pharminox Limited.
303 people are employed at Pharminox Limited.
Pharminox Limited is based in Nottingham, Nottingham.
The NAICS codes for Pharminox Limited are [3254, 32, 32541, 325].
The SIC codes for Pharminox Limited are [2834, 283, 28].